Details of the Drug

General Information of Drug (ID: DMXR8WN)

Drug Name
CYCLOPLATAM
Synonyms Ammine(cyclopentanamine)[(S)-hydroxybutanedioato(2-)-O1,O4]platinum; (S)-(-)-Malatoammine(cyclopentylamine)platinum (II)
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 429.33
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 1
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 7
Chemical Identifiers
Formula
C9H18N2O5Pt
IUPAC Name
azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+)
Canonical SMILES
C1CCC(C1)N.C(C(C(=O)[O-])O)C(=O)[O-].N.[Pt+2]
InChI
InChI=1S/C5H11N.C4H6O5.H3N.Pt/c6-5-3-1-2-4-5;5-2(4(8)9)1-3(6)7;;/h5H,1-4,6H2;2,5H,1H2,(H,6,7)(H,8,9);1H3;/q;;;+2/p-2
InChIKey
OPWOOOGFNULJAQ-UHFFFAOYSA-L
Cross-matching ID
PubChem CID
3035239
CAS Number
109837-67-4
TTD ID
D00DPP

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein kinase C (PRKC) TTYVX59 NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Results of phase II clinical trial of cycloplatam in refractory solid tumors. Vopr Onkol. 2001;47(6):752-6.
2 Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.